COVID-19 associated pulmonary aspergillosis-an unusual manifestation of COVID-19


  • B. Anusuya Department of Pharmacy Practice, C. L. Baid Metha College of Pharmacy, Chennai, Tamil Nadu, India
  • J. Yamini Department of Pharmacy Practice, C. L. Baid Metha College of Pharmacy, Chennai, Tamil Nadu, India



COVID-19, CAPA, Pulmonary aspergillosis, Posaconazole


A recently identified condition known as COVID-19-associated pulmonary aspergillosis (CAPA) is connected to the COVID-19 pandemic and is known as post-COVID complications. More data are awaited, and a consensus criterion was recently published in an effort to spur more research and registries to assist clinical decision-making. However, it is evident that CAPA imposes a COVID-19 illness course that worsens with increased morbidity and mortality. Here we present the case of a 53-year-old male patient admitted to our hospital after recovering from COVID-19. Due to his clinical condition, some investigation criteria were performed and Aspergillus fumigatus was identified in his culture test. Treatment was provided with posaconazole as a first-line drug, and the patient showed a good clinical outcome.


Barber RM, Sorensen RJD, Pigott DM, Bisignano C, Carter A, Amlag JO, et al. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through: a statistical analysis. Lancet. 2022;399(10344):2351-80.

Kakamad FH, Mahmood SO, Rahim HM, Abdulla BA, Abdullah HO, Othman S, et al. Post covid-19 invasive pulmonary Aspergillosis: A case report. Int J Surg Case Rep. 2021;82:105865.

Arastehfar A, Carvalho A, van de Veerdonk FL, Jenks JD, Koehler P, Krause R, et al. COVID-19 associated pulmonary aspergillosis (CAPA)—from immunology to treatment. J Fungi (Basel). 2020;6(2):91.

Dimopoulos G, Almyroudi M-P, Myrianthefs P, Rello J. COVID-19-associated pulmonary aspergillosis (CAPA). J Intens Med. 2021;1(2):71-80.

Bhopalwala H, Mishra V, Do TV, Gudipati M, Ganti SS. COVID-19 infection and late manifestation of pulmonary aspergillosis. J Investig Med High Impact Case Rep. 2022;10:23247096211063332.

Intra J, Sarto C, Beck E, Tiberti N, Leoni V, Brambilla P. Bacterial and fungal colonization of the respiratory tract in COVID-19 patients should not be neglected. Am J Infect Control. 2020;48(9):1130-1.

Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;63(4):e1-60.

Armstrong-James D, Youngs J, Bicanic T. Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis. Eur Respir J. 2020;56:2002554.






Case Reports